正在加載......
許達夫醫師自然診所醫療網
 許達夫醫師自然診所醫療網 進階搜尋
  親近自然 自然健康.生命源自自然 自然就是美
回首頁 討論區
 
X
 
會員帳號 :
會員密碼 :
忘記密碼  加入會員
本網導覽

首頁 > 癌症統計 > 英國癌症統計(大腸直腸癌)

Survival from cancers of the colon and rectum in England and Wales up to 2001

A G Acheson1 and J H Scholefield1

1Section of Surgery, University of Nottingham, University Hospital, Floor E, West Block, Nottingham NG7 2UH, UK

Correspondence: Professor JH Scholefield, E-mail: John.scholefield@nottingham.ac.uk

Colorectal cancer is the third most common malignancy in the 'developed' world, after lung and breast cancer, and causes approximately 16 000 deaths per year in England and Wales. It usually occurs in the seventh or eight decade and has a similar overall incidence in the sexes. Despite improvements in early diagnosis, over recent years up to 30% of large bowel cancers still present as emergencies with obstruction or perforation and approximately 30% present late with metastatic disease.

Despite significant advancements in diagnostics, surgical technique, perioperative and postoperative therapies, many sceptics still suggest that the mortality from this disease has changed very little over the last few decades. The two preceding articles in this supplement of the British Journal of Cancer identify considerable improvements with regard to our management of patients with colorectal cancer in the United Kingdom. These papers report an increasing incidence rate of the disease but more important is the improvement in survival figures for colon cancer in England and Wales with a 40% 5-year survival rate in the late 1980s compared with 48% in the late 1990s. The improvement for rectal cancer is even more marked than for colon cancer. Although the absolute values of 5-year survival are inflated (as discussed by the authors) due to patients excluded from their analysis having a shorter survival period, the survival trends are most striking and encouraging.

So why has the incidence of colorectal cancer increased at the end of the 20th century? This is difficult to fully explain but there are a number of factors that may have contributed. Colonoscopic screening of high-risk individuals with a strong predisposition for colorectal cancer such as a strong family history, adenomatous polyps and inflammatory bowel disease has undoubtedly improved the detection rate of the disease (Atkin et al, 2002). Increased public awareness of the disease along with more willingness to report symptoms to the family doctor may be a significant factor, with consequent earlier presentation of cases. Dietary factors may be important with those consuming high meat, low-fibre diets felt to be at greater risk. Other lifestyle factors such as obesity, falling rates of physical activity and increasing consumption of alcohol may also have played a part.

And why have survival rates improved towards the latter part of the 20th century? Again increased public awareness leading to earlier diagnosis of better stage tumours is important. The introduction of the multidisciplinary team approach to the management of all patients with colorectal cancer has been instrumental in improving the decision making and eventual outcome of these patients (Kelly et al, 2003). Improved training workshops and specialisation of general surgeons has occurred with advances in surgical techniques, particularly in relation to rectal cancer, and this has resulted in the adoption of meticulous surgery in the form of total mesorectal excision (TME) with lower local recurrence rates and improved survival (MacFarlane et al, 1993). Similarly, advances in more effective adjuvant chemo- and radiotherapy have had a significant part to play, although the availability of many of the expensive adjuvant chemotherapeutic agents remains a subject of debate in the United Kingdom (Cammà et al, 2000; Tebbutt et al, 2002). Over the past 20 years there has been much enthusiasm in support of liver resection in patients with metastatic colorectal cancer with many centres reporting excellent results. Regular imaging and detection of operable liver lesions during staging and follow-up of colorectal cancer has also resulted in some survival benefit (Garden et al, 2006).

It is disappointing that survival rates among the more affluent remain better than among the more deprived. We agree with the authors that this suggests that more affluent patients have probably benefited preferentially from progress in early diagnostic procedures and in access to optimal treatment over this period, highlighting an important ongoing challenge for health services.

Despite the encouraging survival trends there is still room for improvement, particularly, as many of our American and European counterparts quote survival figures over 50% (O'Connell et al, 2004). The Department of Health has suggested that these UK statistics do not reflect any progress from the significant investment in cancer care since the publication of the NHS Cancer Plan in 2000. Government targets have been introduced in an attempt to identify 'high risk or alarm symptoms' with the aim of reducing delays between presentation, diagnosis and treatment. Time will tell if these target guidelines will bring any long-term survival benefits to patients in the United Kingdom.

Over the next few years bowel cancer screening by means of faecal occult blood (FOB) testing is being phased in throughout England and Wales. It is hoped that by implementing such a national population screening programme, many earlier stage cancers will be detected and this should reduce disease specific mortality as has been shown in several previous randomised controlled trials (Mandel et al, 1993; Hardcastle et al, 1996; Kronborg et al, 1996).

Despite the disappointing projected trends in survival from rectal cancer, important new developments in the management of the disease allow us to be more optimistic about continuing improved survival rates for colorectal cancer into the 21st century. The outstanding challenge for health services will be to ensure that the projected widening of the deprivation gap does not become a reality and to develop strategies to close this gap in forthcoming years.

Top

References

  1. Atkin WS, Saunders BP, British society for gastroenterology; Association of coloproctology for Great Britain and Ireland (2002) Surveillance guidelines after removal of colorectal adenomatous polyps. Gut 51(Suppl 5): V6–V9 | Article | PubMed |
  2. Cammà C, Giunta M, Fiorica F, Pagliaro L, Craxì A, Cottone M (2000) Preoperative radiotherapy for resectable rectal cancer: a meta-analysis. JAMA 284: 1008–1015 | Article | PubMed | ISI | ChemPort |
  3. Garden OJ, Rees M, Poston GJ, Mirza D, Saunders M, Ledermann J, Primrose JN, Parks RW (2006) Guidelines for resection of colorectal cancer liver metastases. Gut 55(Suppl 3): iii1–iii8 | Article | PubMed |
  4. Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, James PD, Mangham CM (1996) Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 348: 1472–1477 | Article | PubMed | ISI | ChemPort |
  5. Kelly MJ, Lloyd TD, Marshall D, Garcea G, Sutton CD, Beach M (2003) A snapshot of MDT working and patient mapping in the UK colorectal cancer centres in 2002. Colorectal Dis 5: 577–581 | Article | PubMed | ChemPort |
  6. Kronborg O, Fenger C, Olsen J, Jørgensen OD, Søndergaard O (1996) Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 348: 1467–1471 | Article | PubMed | ISI | ChemPort |
  7. MacFarlane JK, Ryall RD, Heald RJ (1993) Mesorectal excision for rectal cancer. Lancet 341: 457–460 | Article | PubMed | ISI | ChemPort |
  8. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, Ederer F (1993) Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 328: 1365–1371 | Article | PubMed | ISI | ChemPort |
  9. O'Connell JB, Maggard MA, Ko CY (2004) Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 96: 1420–1425 | PubMed |
  10. Tebbutt NC, Cattell E, Midgley R, Cunningham D, Kerr D (2002) Systemic treatment of colorectal cancer. Eur J Cancer 38: 1000–1015 | Article | PubMed | ISI | ChemPort |


本網站所有圖文所有權屬許達夫醫師自然診所及新活力健康事業有限公司 請勿拷貝盜用, 本網保留法律追溯權!

地址:台中市南屯區向心路90號 服務專線:04-2475-3600 傳真:04-24753602       本網站是由瑟琳納廣告 建置